Abstract:Background Upadacitinib (UPA) is the 1st oral, reversible, selective Janus kinase inhibitor that approved in China for moderately to severely active Crohn’s disease (CD) treatment. UPA demonstrated significantly greater efficacy compared with placebo (PBO) in phase 3 global multicenter, double-blind, PBO-controlled induction U-EXCEL and U-EXCEED studies. This analysis reports the efficacy and safety results on a sub-analysis of Chinese from the combined 2 induction studies. Methods Eligible patients with an average daily very soft/liquid stool frequency (SF) ≥4 and/or abdominal pain score (APS) ≥2, plus a Simple Endoscopic Score for CD (excluding the narrowing component) ≥6 (≥4 for isolated ileal disease) were randomized (2:1) to UPA 45 mg or PBO for 12 weeks. Patients receiving corticosteroid at baseline began a steroid taper at week 4 per protocol. This analysis included Chinese subjects from global population. The 2 induction studies were combined for each analysis set. Clinical remission per PROs was defined as average daily very soft or liquid SF ≤ 2.8 and average daily AP score ≤1.0 and both not greater than baseline. Endoscopic response was defined as decrease in SES-CD>50% from baseline (or for subjects with an SES-CD of 4 at baseline, at least a 2-point reduction), as scored by central reviewer. Results Of the 1021 patients enrolled in the 2 induction studies, 120 from China were included in the analysis. Baseline demographic and characteristics were mostly similar with a few exceptions. A significantly higher percentage of Chinese patients who received UPA 45mg QD than those received PBO had clinical remission per PROs at week 12 (70.9% vs 22.0%, p<0.0001). At week 4, clinical remission per PROs was achieved by a numerically greater proportion of patients receiving UPA (51.9%) than PBO (17.1%). At week 12, in patients taking corticosteroids for CD at baseline, a numerically greater proportion of patients receiving UPA (72%) discontinued corticosteroid use and achieved clinical remission per PROs than did patients receiving PBO (30%). A significantly higher percentage of Chinese patients who received UPA than those received PBO had endoscopic response at week 12 (64.6% vs 12.2%, p<0.0001). The rate of adverse events (AEs) in the UPA group was comparable to PBO group. There were no treatment-emergent deaths in either group. In the Chinese population, AEs of special interest occurred at similar rates between PBO and UPA group. No malignancies, adjudicated major cardiovascular events, or venous thromboembolic events were reported. Conclusion Similar to global population, Chinese patients treated with UPA 45mg achieved clinical and endoscopic outcomes at higher rates than did patients receiving PBO, with a tolerable safety profile.

Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease

IDDF2024-ABS-0420 Successful Treatment with Upadacitinib in Four Patients of Intestinal Behcet’s Disease with Ineffective Anti-Tnf Therapy

Case Report: Successful Remission with Upadacitinib in a Young Patient with Anti-Tnf-refractory Intestinal Behçet’s Disease

Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report

Successful treatment of Crohn's disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review

Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review

JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune-Related Colitis Triggered by CTLA-4 and PD-1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report

Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis

Short-Term Use of Upadacitinib in Combination with Biologic Therapy for Inducing Clinical Remission in Patients with Active Inflammatory Bowel Disease.

Coexistence of ankylosing spondylitis and Behçet's disease: Successful treatment with upadacitinib

Tofacitinib As an Alternative Therapy for Refractory Intestinal Behçet’s Syndrome

Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib

A Case of Refractory Intestinal Behçet's Disease Treated with Tocilizumab, a Humanised Anti-Interleukin-6 Receptor Antibody.

Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients

Efficacy of Upadacitinib as a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series

Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report

Efficacy of Induction Upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn's Disease

Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report

Case report: Exploration of abrocitinib in the treatment of refractory chronic spontaneous urticaria: a case series

Upadacitinib sustained-release tablets for the treatment of chronic refractory gouty arthritis: a case report and literature review

The Successful Use of Upadacitinib as Monotherapy for Hidradenitis Suppurativa and Ulcerative Colitis in the Setting of Refractory Disease